About This Research Desk

What Carolina Peptide is

Carolina Peptide is an independent editorial desk covering three research peptides organized around soft-tissue and connective-tissue repair: GLOW (a three-peptide combination), KPV (a gut-focused anti-inflammatory tripeptide), and TB-500 (an actin-binding fragment of thymosin beta-4), with TB-500 as the lead compound. Each has its own page; a comparison page reads them side by side across mechanism, evidence depth, and regulatory status; and a single shared reference list aggregates every citation used across all three.

The organizing discipline here is quantitative wherever the literature allows it: species and sample size, dose or dose-range, and effect size — a percentage, a hazard figure, an mg/kg — rather than adjectives. Where a finding rests on 40 human volunteers and where it rests on a single mouse-colitis model are two very different evidentiary positions, and this desk states which is which every time.

How it is compiled

Two rules govern this desk. First, every factual claim traces to a numbered citation — peer-reviewed, PubMed-indexed literature with a DOI or PubMed link, gathered on the references page. Findings drawn from a review article rather than a primary study are labeled as such. Second, evidence is reported at the strength it was actually measured, not the strength marketing language implies: a Phase 1 safety trial in 40 healthy volunteers is described as exactly that, not extrapolated into a claim about efficacy; a combination product like GLOW is described as having zero blend-level trials, even though its individual ingredients are separately well studied. Where a fragment-versus-full-protein distinction complicates a claim — as it does throughout the TB-500 literature — this desk states the complication rather than smoothing over it.

What it is not

Carolina Peptide is not a pharmacy, clinic, or vendor of any kind. It does not sell, source, or broker GLOW, KPV, TB-500, or any of their constituents, and has no affiliate relationship with any research-chemical supplier. It does not recommend a dose, a schedule, or a route of administration for any person, and none of the compounds discussed here is FDA-approved for human use. Two of the three peptides discussed — TB-500 directly, and GLOW through it — are prohibited in tested competitive sport. Readers with a specific medical question should consult a licensed clinician. Editorial corrections — an outdated citation, a newly published trial — can be sent via the contact page; this desk reads that correspondence carefully and cannot respond to requests for medical advice.